Our portfolio company AOA Dx has achieved a significant milestone in ovarian cancer diagnostics with the validation of its multi-omic, AI-powered blood test. A recent peer-reviewed study highlighted by Nancy Lapid for Thomson Reuters demonstrated 92% accuracy across all ovarian cancer stages and 88% accuracy for early-stage (Stage I–II) disease.
Ovarian cancer remains the fifth leading cause of cancer-related deaths among women, mainly due to late diagnosis. AOA Dx's approach provides a faster and more reliable diagnostic pathway during the critical window when intervention can make the greatest difference.
We're proud to support CEO Oriana Papin-Zoghbi and the AOA Dx team as they advance precision diagnostics in oncology.
Read the article by Nancy Lapid in Reuters here.
Ovarian cancer remains the fifth leading cause of cancer-related deaths among women, mainly due to late diagnosis. AOA Dx's approach provides a faster and more reliable diagnostic pathway during the critical window when intervention can make the greatest difference.
We're proud to support CEO Oriana Papin-Zoghbi and the AOA Dx team as they advance precision diagnostics in oncology.
Read the article by Nancy Lapid in Reuters here.